AMGN Stock Recent News

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Key acquisitions since 2022 increased Amgen's rare disease pipeline and footprint in the market, with the company poised to benefit from the rare disease market's 10.35% CAGR up to 2037. A growing portfolio of biosimilar products will drive double-digit sales growth in the coming decade. The immense growth potential in both its rare disease and biosimilar portfolios is essential for Amgen to offset patent cliff headwinds.

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen offers an economic moat with patent protection, a robust pipeline, and strong execution, making it a defensive long-term investment. Double-digit sales growth in key drugs and a burgeoning biosimilars business support Amgen's solid revenue and earnings outlook. The pipeline, especially MariTide for obesity and biosimilars to blockbuster oncology drugs, provides meaningful future growth catalysts.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

In the latest trading session, Amgen (AMGN) closed at $295.18, marking a -1.73% move from the previous day.

Generating passive income is great for investors, and holding dividend-paying stocks is an excellent way to do that. However, not all corporations that pay dividends will be attractive to income seekers.

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid, offering defensive characteristics, capital preservation, and yield over high-growth potential. The diversified product base and growing biosimilars segment reduce concentration and patent cliff risks, supporting Amgen's stability as a portfolio anchor. Biosimilars face execution, pricing, and demand risks, but continued strong growth could offset upcoming revenue losses from key patent expirations.